Please login to the form below

Not currently logged in
Email:
Password:

Zydelig

This page shows the latest Zydelig news and features for those working in and with pharma, biotech and healthcare.

Novartis claims a rare win at ESMO for PI3K inhibitor class

Novartis claims a rare win at ESMO for PI3K inhibitor class

Zydelig is among the existing PI3K inhibitors on the market. Three PI3K inhibitors have been approved for blood cancers – namely Gilead Sciences’  Zydelig (idelalisib), Bayer’s Aliqopa (copanlisib) and most recently

Latest news

  • Novartis considers filings for PI3K drug in breast cancer Novartis considers filings for PI3K drug in breast cancer

    At the moment no PI3K inhibitor has been approved for use in breast cancer, although Gilead Sciences’ Zydelig (idelalisib) has been used for certain types of leukaemia and lymphoma for several ... Zydelig has been affected by safety concerns,

  • Bayer bags speedy US approval for lymphoma drug Aliqopa Bayer bags speedy US approval for lymphoma drug Aliqopa

    FDA decision sets the pharma firm up for a showdown with Gilead's Zydelig. ... The FDA has approved Bayer's PI3K inhibitor Aliqopa, setting up a market showdown with Gilead Sciences' Zydelig in follicular lymphoma.

  • Bayer's lymphoma drug copanlisib gets speedy FDA review Bayer's lymphoma drug copanlisib gets speedy FDA review

    Bayer is in pursuit of Gilead Sciences' P13K inhibitor Zydelig (idelalisib), which is already approved for FL and chronic lymphocytic leukaemia (CLL) in the US but hasn't lived up to ... First launched in 2014, Zydelig brought in $168m for Gilead over

  • EU clears AbbVie's leukaemia drug venetoclax EU clears AbbVie's leukaemia drug venetoclax

    have either failed chemoimmunotherapy or are unsuitable for treatment with a B-cell receptor pathway inhibitor such as AbbVie and Johnson &Johnson's Imbruvica (ibrutinib) or Gilead Science's Zydelig (idelalisib).

  • Roche in Roche in "unprecedented" launch period for new medicines

    Gazyva's gains came despite increased competition in the CLL market from drugs such as AbbVie/Johnson &Johnson's Imbruvica (ibrutinib) and Gilead Science's Zydelig (idelalisib) and a failed trial

More from news
Approximately 9 fully matching, plus 17 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics